Table 1.

Clinical characteristics of patients with membranous nephropathy according to antibody profile

Characteristics	Phospholipase A2 Receptor 1+/Intracellular+ (n=118)	Phospholipase A2 Receptor 1+/Intracellular- (n=64)	Phospholipase A2 Receptor 1−/Intracellular+ (n=64)	Phospholipase A2 Receptor 1−/Intracellular− (n=31)
Sex (M/F)	84/34	45/19	47/17	21/10
Age (yr)	61 (50–72)	63 (46–70)	57 (42–67)	55 (43–71)
Membranous nephropathy histologic stage (%)
I	19	24	26	45
II	44	49	50	33
III	29	23	15	11
IV	8	4	9	11
Treatment (%)
Steroids/ACEia	80	78	85	78
Cyclosporine A	18	30	14	16
Cytotoxic	43	44	33	32
Rituximab	7	22	16	19
Clinical characteristics
Proteinuria (g/d)
Baseline	5.6 (3.3–9.7)	6.0 (3.3–9.8)	3.4 (1.8–6.4)*	4.4 (2.6–6.4)*
12 mo	1.7 (0.4–4.4)	1.8 (0.6–4.3)	1.3 (0.3–3.5)	0.5 (0.1–2.7)**
CKD-EPI (ml/min per 1.73 m2)
Baseline	69 (46–99)	66 (47–100)	72 (43–99)	89 (63–103)**
12 mo	74 (48–99)	78 (59–99)	67 (44–101)	96 (72–103)**

Patients both PLA2R1 and intracellular antibody positive; patients PLA2R1 positive and intracellular antibody negative; patients PLA2R1 negative and intracellular antibody positive; and patients both PLA2R1 negative and intracellular antibody negative. Data are reported as number and percentage or median with interquartile range. Mann–Whitney U or Kruskal–Wallis tests were used for continuous variables, respectively, for two or more of two unpaired samples, and chi-squared or Fisher’s exact tests were used for categorical variables. Two-tailed P values ≤0.05 were considered as significant. *P=0.001 versus A and B; **P=0.001 versus A, B, and C. PLA2R1, phospholipase A2 receptor 1; M, male; F, female; ACEi: angiotensin converting enzyme inhibitors; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.

^aSteroids and ACEi were given alone or in association with other drugs.